Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) Revenue
Annual & quarterly revenue history · segment & region breakdown
OCUL · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsOcular Therapeutix, Inc. trailing twelve-month (TTM) revenue is $0.05B, a decrease of 18.67% year-over-year from $0.05B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.05B | -$0.01B | -18.67% |
| 2024-12-31 | $0.06B | +$0.01B | +9.03% |
| 2023-12-31 | $0.06B | +$0.01B | +13.49% |
| 2022-12-31 | $0.05B | +$0.01B | +18.32% |
| 2021-12-31 | $0.04B | +$0.03B | +150.08% |
| 2020-12-31 | $0.02B | +$0.01B | +311.71% |
| 2019-12-31 | $0.00B | +$0.00B | +112.41% |
| 2018-12-31 | $0.00B | +$0.00B | +3.48% |
| 2017-12-31 | $0.00B | +$0.00B | +1.91% |
| 2016-12-31 | $0.00B | +$0.00B | +7.83% |
Compare revenue vs peers
BiotechnologyCompare OCUL revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ocular Therapeutix, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ocular Therapeutix, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ocular Therapeutix, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
OCUL revenue · 4 questionsOCUL's trailing twelve-month (TTM) revenue is $0.05B. That is a decrease of 18.67% year-over-year from $0.05B in FY2025.
▸ Source: FMP · Ocular Therapeutix, Inc. SEC filings · GAAP · Ocular Therapeutix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026